Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Stephen Hill Insider Profile
11 Followers
Stephen Hill, Director at Gyre Therapeutics, holds 1.19K shares in Gyre Therapeutics (Ticker: GYRE), holds 12.75K shares in Lipocine (Ticker: LPCN), holds 0.00 shares in Arqule (Ticker: ARQL).
Profitable Transactions
4 out of 6 Profitable Transactions
Average Return
+27.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Stephen Hill holds in companies
Most Profitable Insider Trade
The most profitable trade made by Stephen Hill
Stephen Hill's Trading History
Gyre Therapeutics
Sep 06, 2018
Director
Uninformative Sell
1.91K
$18.20K
Lipocine
Jan 02, 2018
Director
Uninformative Sell
4.34K
$73.31K
Arqule
―
―
―
$0.00
Cellectar Biosciences
Jun 08, 2020
Director
Informative Buy
19.26K
$59.94K
List of latest transactions for each holding click on a transaction to see Stephen Hill's performance on stock
You May Also Like
Stephen Hill insider profile FAQ
What is the percentage of profitable transactions made by Stephen Hill?
The percentage of profitable transactions made by Stephen Hill is 67%.
What is the average return per transaction made by Stephen Hill?
The average return per transaction made by Stephen Hill is 27.40%.
What stocks does Stephen Hill hold?
Stephen Hill holds: GYRE, LPCN, ARQL, CLRB stocks.
What was Stephen Hill’s latest transaction?
Stephen Hill latest transaction was an Uninformative Sell of $1.91K.
What was Stephen Hill's most profitable transaction?
Stephen Hill’s most profitable transaction was an Informative Buy of LPCN stock on November 13, 2014. The return on the trade was 166.00%.
What is Stephen Hill's role in Gyre Therapeutics?
Stephen Hill's role in Gyre Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.